Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy
Abstract: Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR). Methods: 68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol; Group B consisted of 17 patients receiving enhanced therapy; Group C consisted of 17 patients receiving regular therapy and probucol; Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ± 0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed. Results: 1) The fundi of Group A and Group C were significantly improved (P < 0.05), and there was no significant difference between the fundi of Group A and of Group C after therapy (P > 0.05); but the difference between the fundi of Group B and of Group D was not statistically significant (P > 0.05). 2) The best corrected visual acuity of Group A and Group C was improved significantly (P < 0.05), and there was no significant difference between the best corrected visual acuity of Group A and of Group C (P > 0.05); but the best corrected visual acuity of Group B and Group D did not change significantly (P > 0.05). 3) The TC and LDLC level of Group A and Group C decreased significantly (P < 0.05); The TC and LDLC level of Group B and Group D did not change significantly (P > 0.05); There was no significant difference between the TC and LDLC level of Group A and of Group C (P > 0.05). Conclusion: The efficacy of probucol for nonproliferative diabetic retinopathy is significant with less complications.
文章引用: 蒋苏平 , 陈忠平 (2014) 丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察。 眼科学， 3， 13-18. doi: 10.12677/HJO.2014.32003
 Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
 Virag, L. and Szabó, C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacological Reviews, 54, 375-429.
 Obrosova, I.G., Pacher, P., Szabo, C., et al. (2005) Aldose reductase in-hibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes, 54, 234-242.
 Yokoi, M., Yamagishi, S., Takeuchi, M., et al. (2005) Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. British Journal of Ophthalmology, 89, 673-675.
 Kowluru, R.A., Tang, J. and Kern, T.S. (2001) Abnormalities of retinal metabolism in diabetes and experimental galactosemia VII. Effect of long-term adm inistration of antioxidants on the development of retinopathy. Diabetes, 50, 1938-1942.
 Rema, M., Srivastava, B.K., Anitha, B., et al. (2006) Association of serum lipids with diabetic retinopathy in urban South Indians—The Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2. Diabetic Medicine, 23, 1029-36.
 廖璞, 王淑琴, 王宁等 (2003) NF-Kp在糖尿病大鼠肾脏和血液单个核细胞中的表达. 基础医学与临床, 3, 328-331.
 王拥军 (2001) 应加强颈动脉粥样硬化的基础和临床研究. 中华神经科杂志, 5, 257.
 Du, Y., Miller, C.M. and Kem, T.S. (2003) Hyperglycemia increases mi-tochondrial superoxide in retina and retinal cells. Free Radical Biology Medicine, 35, 1491-1499.
 Kowaltowski, A.J., Castilho, R.F. and Vercesi, A.E. (2001) Mitochondrial permeabilitytransition and oxidative stress. FEBS Letters, 495, 12-15.
 陈永东, 许讯 (2007) 氧化应激在糖尿病视网膜病变中的作用研究进展. 中华眼底病杂志, 23, 298-300.
 O’Leary, V.J., Tilling, L., Fleetwood, G., et al. (1996) The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. Atherosclerosis, 119, 169-179.
 Bamhart, R.L., Busch, S.J. and Jackson, R.L. (1989) Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro:probucol degradation Precedes lipoprotein oxidation. The Journal of Lipid Research, 30, 1703-1710.
 Baumstark, M.W., Aristegui, R., Zoller, T., et al. (1992) Probucol, incorporated into LDL particles in vivo, inhibits generation of lipid peroxides more effectively than endogenous antioxidants alone. Clinical Biochemistry, 25, 395-397.
 Masana, L., Bargallo, M.T., Plana, N., et al. (1991) Effeetiveness of probucol inreducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. American Journal of Cardiology, 68, 863-867.